Actualities of Hungarian

pharmaceutical financing

Newsletter

News, current issues

- Legislations come into force from February 2013: EüM Decree No. 4/2000. (2013.02.08.); EüM Decree No. 43/2005. (2013.02.08.)
- NEWS: 01/03/2013 Preferred biological process was started. Further information: link
- NEWS: "Hungarian pharmaceutical market is against trends world-wide" link
- NEWS: "The itemised financing ensures patients' supply irrespective of the financial status of hospitals" link
- NEWS: "The total debt of hospitals rose to 115 billion HUF during the fourth quarter of the last year" link
- STUDY: "State Audit Office of Hungary: The financial status of hospitals changed favourably, while there are still operating risks" Short summary: link Study: link
- STUDY: "Confidence in health service did not alter over the last four years" link

Macro approach to financing healthcare and medicinal products

Balance of the Health Insurance Fund

					Billion HUF
		2013 original		2013	
Health Security Fund	2012. I-XII.	appropriation	I.	% of appropriation	% of last year
Total of Budgetary Expenditures	1 791,3	1 804,3	141,6	94,2%	100,9%
Curative preventive provisions	842,1	880,6	65,8	89,6%	105,3%
Medicine subsidies	315,1	280,0	23,1	99,0%	86,0%
Total Of Budgetary Revenues	1 744,3	1 804,3	160,6	106,8%	120,4%
Social Security Contributions	854,2	727,0	71,1	117,3%	109,9%
Contribution of Pharmaceutical Manufacturers and Wholesalers	75,0	49,0	5,5	135,8%	103,0%
Balance	-47,0	0,0	19,0		-269,6%


The 2013 budget counts with 0,7% increase in the expenditure and 3,4% increase in the revenues, while the balance is nil. The social security contribution is planned to be less with 15% than last year fulfilment, and this gap is filled with central budget contribution. The medicine subsidies plan are lower with 11% than last year expenses but higher with 2 billion HUF than last year budget plan.

In the first month of 2013 the Health Security Fund produced a 13,4% surplus mainly because of the higher social security contributions (+17%) and lower spending. The in- and outcare expenditure was 10% lower than the budget plan proportional to that time interval.

Changes to subsidised medicinal product categories


	Changes ir	n the publi	ic drug list	:			
	2012 Oct.	2012 Nov.	2012 Dec.	2013 Jan.	2013 Feb.	2013 Mar.	2013
Number of new products	50	26	33	43	34	26	103
Number of new Al	3	2	0	2	0	5	7
Number of delisted products	65	44	14	88	19	20	127
Prices							
Decrease	789	24	11	61	13	14	88
Increase	0	0	1	0	0	1	1

Dynamics of the sales/circulation of prescription-only-medicine





nalysis based on OEP-PUI



While the turnover of reimbursed medicines in pharmacies decreased by 1.6% in 2012 (measured in DOT), the total medicine subsidy of Health Security Fund was lower by 17%. The main causes of this saving were the reallocation of the drug budget (expensive therapies were transferred to the hospital budget), and the new process of reference price system which lead to significant cuts in prices and reimbursements.

Drug sales in the first month of 2013 was 2,1% lower than the same period last year, while the average reimbursement per DOT remained the same level as from the last reference price procedure.

HealthWare Consulting Ltd.

1

ΤI NG

meta

Product offering

U S

references.

We collect the available informa-

tion, evidence in related articles,

As the first step of systematic re-

search of the scientific literature we define the relevant keywords.

Then we present the evidence charts, it is followed by organiza-

We are able to make an exact summary of the results with statistical methods, which is based on the systematic research of scientific literature that led to compiling the parameters of evidence charts.

tion and comparative analysis.

Meta - analysis

More details: link

directives, studies, research.



Survey

analysis

of

pharmaceutical market



Market data

Newsletter

Marketing authorisation information

EMA	OGYI	2012 - Q4	EMA	OGYI	January 2013	EMA	OG
64	427	New brands	13	95	New brands	7	2
798	4 230	New SKUs	184	773	New SKUs	137	18
	64	64 427	64 427 New brands	64 427 New brands 13	64 427 New brands 13 95	64 427 New brands 13 95 New brands	64 427 New brands 13 95 New brands 7

TOP10 MAH by all reimbursement paid in January 2013

		TOP 10 - MAH	Reimbursement
		Novartis Europharm Limited	1 420 732 343 HUF
		Richter Gedeon Vegyészeti Gyár NyRt.	1 184 097 377 HUF
		EGIS Gyógyszergyár Nyrt.	1 161 088 662 HUF
	$\langle \rangle$	SANOFI-AVENTIS Zrt.	990 283 718 HUF
13 712 186 HUF	9 289 065 885 HUF	Eli Lilly Nederland B. V.	930 467 473 HUF
63%	37%	Novo Nordisk A/S	792 687 731 HUF
		GlaxoSmithKline Kft.	782 152 253 HUF
		Boehringer Ingelheim International GmbH	689 197 493 HUF
		AstraZeneca Kft.	680 996 434 HUF
		Novartis Hungária Kft.	657 362 400 HUF
		Source: Healthware analysis based on the sales turnover that pharma	cies produced from POM

TOP10 BRAND by all reimbursement paid in January 2013

		TOP 10 - BRAND	Distributor	Reimbursement
		GLIVEC	Novartis Hungária Kft.	624 474 604 HUF
		CLEXANE	SANOFI-AVENTIS Zrt.	570 973 347 HUF
		SPIRIVA	Boehringer Ingelheim Pharma Gesellschaft m. b.	496 996 820 HUF
		RISPERDAL	Janssen-Cilag Kft.	480 183 417 HUF
20 844 681 479 HUF	4 058 096 592 HUF	SYMBICORT	AstraZeneca Kft.	404 442 385 HUF
84%	16%	SERETIDE	GlaxoSmithKline Kft.	339 735 243 HUF
		HUMULIN	Lilly Hungaria Kft.	322 176 634 HUF
		SUTENT	Pfizer Kft.	306 552 877 HUF
		LANTUS	SANOFI-AVENTIS Zrt.	286 614 601 HUF
		COVEREX	EGIS Gyógyszergyár Nyrt.	225 946 664 HUF
		Source: Heal	thware analysis based on the sales turnover that pharmac	ies produced from POM

TOP10 ATC by all reimbursement paid in January 2013



International price comparisons of oral risperidon substance containing SKU, based on EF prices - Case study

In our case study we present statistics related to oral risperidon (N05AX08) agent containing formulations of 10 European countries, which are based on the price and product information of formulations effective in 1st January 2011.

We investigated the hypothesis, that the wider the range of products, the sharper competition will occur in terms of the prices. Based on this it can be expected, that the bubble of the countries will be located around the diagonal, which can be seen in the coordinate system. Risperidon market of Germany (GER), Spain (ESP), Portugal (POR), Greece (GRE), Croatia (CRO) and Austria (AUS) showed a corresponding picture. In the case of these countries, it is important to emphasize, that in all countries the deviation of NTK calculated at producer price is low. The reason for that in the case of Germany can be the strict rules of fixing, in the case of Spain can be the rules of fixing and the special rules related to the reimbursement of original products resulting price reduction, and in the case of Greece can be the officially defined price cuts.

The NTK deviation calculated at producer price of the 01.01.2011 drug list of Hungarian risperidon agent containing formulations showed to be average in the light of the international comparison. In the case of Bulgaria the strict official pricing based on the international reference pricing results the low producer price NTK, despite the fact that the number of formulations with public price on the Bulgarian market is among the lowest. In the case of Finland a strong generic incentive was operated besides the fixing system, in which when the substitution is refused, the difference in prices is had to be paid by the patient (above a defined amount). The risperidon market of Sweden shows significant differences in two of the three studied indicators, which is certainly caused by the special reimbursement system and the special generic incentive system of Sweden. In Sweden the "winner takes it all" principle is prevail, in the given period the formulation of the producer, who offered the lowest price, can take the turnover of the whole market. The producers, who offer an approximately similar low price can reach turnover only in the case, when the formulation of the producer, who offered the lowest price, is not available. However, they do not delist and force the original producers to lower their prices, doctors can also prescribe the substitution, patients do not have to pay the difference in price.


With the use of standardized international price data, besides the above issue, strategic, situation assessing, decision support analysis can be conducted in several other topics such as:

- defining, clarifying pricing objectives
- analyzing price strategy of competitors
- product life cycle pricing issues
- international price comparisons
 local and international reference pricing
- assessment of the risks of parallel import


Average number of medical sales reps; 01/2013

All	1 493
Medicinal products	1 271
Medical aids	202
Both	20

Drug reimbursement by legal title; 01/2013



turnover that pharmacies produced from POM



Explanation of the figure:

- "x" axis: considering NTK calculated at producer price (considering products with same NTK only once) NTK average of the three cheapest formulations at producer price (in €)
- "y" axis: number of formulations with price in public lists of countries
- radius of bubbles: deviation of daily therapeutic cost of formulations calculated at producer price

HealthWare Consulting Ltd.

1093 Budapest, Közraktár street 30-32. 6th floor (RiverPark Offices) | +36 1 279 1083 | www.healthware.hu

Subscribe Unsubscribe